New combo therapy hopes to tackle rare skin cancer
NCT ID NCT04930653
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining a targeted antibody drug (mogamulizumab) with a procedure that treats white blood cells with light (extracorporeal photopheresis) can better control erythrodermic cutaneous T-cell lymphoma, a rare skin cancer. About 34 adults with advanced stages of the disease will receive both treatments. The study aims to see how many patients respond and to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mogamulizumab (a monoclonal antibody) combined with extracorporeal photopheresis (a procedure that treats white blood cells with light)
- What this could lead to
- If successful, this combination could offer a new, more effective treatment option for people with advanced skin lymphoma, potentially improving response rates and disease control.
- What could go wrong
- This is a small, early-phase (phase II) trial with only 34 participants, so results may not apply to everyone. Side effects from the drugs or procedure are possible, and the combination may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULOTROPIC MYCOSIS FUNGOIDES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mayo Clinic
RECRUITINGScottsdale, Arizona, 85259, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute of Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Combination therapy aims to boost response in rare skin cancers
- Massive T-Cell lymphoma database aims to unlock new insights
- Engineered donor cells take aim at tough blood cancers in early trial
- New drug cocktail aims to tackle tough skin cancer
- New drug combo targets Hard-to-Treat skin cancer
- Rare skin disease patients develop even rarer lymphoma – scientists investigate why